Estradiol Transdermal Patch Preparations for Transgender Hormone Therapy
For transgender women (male-to-female), transdermal estradiol patches delivering 50–100 µg per 24 hours are the standard preparations, applied twice weekly or weekly depending on the formulation, with the goal of maintaining serum estradiol levels around 200 pg/mL. 1
Available Patch Strengths and Dosing
The most commonly available transdermal estradiol patch strengths worldwide include:
- 25 µg/day patches – available in approximately 20 countries 2
- 50 µg/day patches – the most widely available strength globally, present in 32 countries 2
- 75 µg/day patches – available in select markets 3
- 100 µg/day patches – widely available and considered standard adult maintenance dosing 4
Application frequency: Patches are typically changed either twice weekly (every 3–4 days) or once weekly (every 7 days), depending on the specific brand formulation 4, 5, 6
Recommended Dosing for Transgender Women
Starting dose: The Endocrine Society guidelines recommend initiating therapy with transdermal estradiol at doses that achieve physiologic female estradiol levels 1
Target serum levels:
- Maintain serum estradiol at approximately 200 pg/mL (the mean daily level for premenopausal women) 1
- Serum testosterone should be suppressed to the female range (<55 ng/dL) 1
Practical dosing approach:
- Begin with 50 µg/day patches and titrate upward based on clinical response and serum estradiol monitoring 7, 8
- For younger transgender women or those requiring higher doses, 100 µg/day patches may be necessary to achieve target estradiol levels 8, 4
- The dose range of 25–100 µg daily via transdermal delivery represents the standard spectrum for hormone therapy 7, 4
Advantages of Transdermal Route for Transgender Patients
Transdermal estradiol is strongly preferred over oral formulations for transgender women due to significantly lower thromboembolism risk. 1
Key safety advantages include:
- Avoids first-pass hepatic metabolism, reducing procoagulant effects and venous thromboembolism (VTE) risk 8, 1
- Does not increase sex hormone-binding globulin (SHBG), thyroid-binding globulin, or cortisol-binding globulin as oral estrogens do 8
- Does not elevate triglycerides or inflammatory markers like C-reactive protein 8
- Particularly important given the 20-fold increase in VTE risk reported in transgender women using oral estrogens, especially ethinyl estradiol 1
Monitoring and Dose Titration
Serum estradiol measurement is essential for dose optimization in transgender hormone therapy, particularly when:
- Symptoms do not improve with escalating doses 8
- Switching from oral to transdermal administration 8
- Verifying adequate estradiol delivery in patients with variable absorption 9
Important monitoring caveat: Clinicians should not use follicle-stimulating hormone (FSH) levels to assess adequacy of estrogen replacement, as FSH may remain elevated despite sufficient tissue estrogen effect 4, 10
Antiandrogen Combination Therapy
Transdermal estradiol should be combined with an antiandrogen to achieve adequate testosterone suppression in transgender women 1:
- Spironolactone – directly inhibits testosterone secretion and androgen receptor binding 1
- Cyproterone acetate – progestational compound with antiandrogenic properties, widely used in Europe 1
- GnRH agonists (e.g., goserelin acetate) – highly effective for testosterone suppression with low adverse reaction rates 1
Contraindications and Special Populations
Absolute contraindication: Active or history of venous thromboembolism is traditionally considered a contraindication, though emerging evidence suggests transdermal estradiol may be safer than oral formulations in this setting 7
Tobacco cessation is mandatory for transgender women initiating estrogen therapy to minimize cardiovascular and thromboembolic complications 1
Thrombophilia screening should be restricted to patients with personal or family history of VTE, not performed routinely 1
Practical Formulation Considerations
Matrix versus reservoir patches: Modern matrix-type patches incorporating lauric acid provide more stable estradiol delivery with lower coefficients of variation (29–41%) compared to older reservoir patches (63%) 5
Seven-day patches demonstrate sustained pharmacokinetic performance throughout the full week of wear, with estradiol levels proportional to patch strength and maintained physiologic estrone-to-estradiol ratios 3, 11
Adhesion and tolerability: Once-weekly patches show significantly better adhesion than twice-weekly formulations while maintaining similar skin irritation profiles 11
Duration of Therapy
Hormone therapy for transgender women is typically lifelong, as discontinuation would result in return of endogenous testosterone production and reversal of feminizing effects 1
Dose reduction with aging: Consider reducing estradiol dose as patients advance in age to minimize long-term cardiovascular and thrombotic risks, similar to recommendations for cisgender women 7